Soumya Raghuvanshi

Sir, I just had a couple of questions from my side. Firstly, on Salt Lake. Salt Lake continues to deliver higher ARPOB, driven by robotic surgeries and complex procedures. Going forward, do you see ARPOB growth being largely specialty led? Or is there stil l scope for tariff revisions across key departments?

Okay, sir. Understood. Sir, my next question is, last quarter, you had indicated that the restructuring exercise for Dumdum was largely complete and the focus has shifted towards higher ARPOB, departments such as cardiac surgery and advanced urology. How h as the contribution from these newer specialties evolved in Q1? And when should investors expect meaningful revenue acceleration from Dumdum?